Vinva Investment Management Ltd Sells 1,055 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vinva Investment Management Ltd lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,597 shares of the biopharmaceutical company’s stock after selling 1,055 shares during the period. Vinva Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,708,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $754.87 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $82.95 billion, a P/E ratio of 18.68, a PEG ratio of 2.91 and a beta of 0.15. The stock’s 50 day moving average is $913.54 and its 200 day moving average is $1,020.69. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20.

Analysts Set New Price Targets

REGN has been the subject of a number of recent research reports. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,107.29.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.